MK-0773

MK-0773‏‎ is a Selective Androgen Receptor Modulator (SARM) that was developed by Merck & Co. for the treatment of sarcopenia, a condition characterized by loss of muscle mass and strength. The compound is also being investigated for its potential use in the treatment of other conditions such as osteoporosis and cachexia.

History

MK-0773‏‎ was first synthesized by Merck & Co., a multinational pharmaceutical company based in the United States. The compound was developed as part of the company's research into SARMs, a class of drugs that selectively bind to androgen receptors in the body.

Mechanism of Action

As a SARM, MK-0773‏‎ works by selectively binding to androgen receptors in the body. This selective binding allows the compound to exert its effects on specific tissues, such as muscle and bone, without affecting other tissues that also contain androgen receptors. This selectivity is believed to reduce the risk of side effects associated with traditional androgenic drugs.

Clinical Trials

MK-0773‏‎ has undergone several clinical trials to evaluate its safety and efficacy. In a Phase II trial, the compound was found to increase lean body mass in postmenopausal women with sarcopenia. However, the trial also found that MK-0773‏‎ did not significantly improve muscle strength or physical function.

Potential Uses

While MK-0773‏‎ was initially developed for the treatment of sarcopenia, its mechanism of action suggests that it could be useful in the treatment of other conditions. For example, the compound's ability to increase bone density could make it a potential treatment for osteoporosis. Similarly, its ability to increase muscle mass could make it a potential treatment for cachexia, a condition characterized by severe muscle wasting.

See Also

• Selective Androgen Receptor Modulator
• Sarcopenia
• Osteoporosis
• Cachexia

This article is a stub related to pharmacology. You can help WikiMD by expanding it!